KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome.
about
Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profilingAdenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort studyMalignant adenomyoepithelioma combined with adenoid cystic carcinoma of the breast: a case report and literature review.Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsAdenoid cystic carcinoma of breast: Recent advances.TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype.The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancerIdentification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.Triple-negative breast cancer: are we making headway at least?Management of unusual histological types of breast cancer.Update on triple-negative breast cancer: prognosis and management strategiesAdenoid cystic carcinoma of the breast, 20 years of experience in a single center with review of literature.A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.Adenoid cystic carcinoma of the breast: Review of the literature and report of two casesHER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland.Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.Biomarkers for Basal-like Breast Cancer.Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.Histological types of breast cancer: how special are they?Triple-negative breast cancer: present challenges and new perspectives.Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers.Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers.Differential expression and clinical significance of epithelial-mesenchymal transition markers among different histological types of triple-negative breast cancer.Adenoid cystic carcinoma of the breast: Experience at a tertiary care centre of Northern IndiaA Practical Approach to the Use of Immunohistochemistry in the Diagnosis and Management of Breast Disease
P2860
Q26781643-5960F15B-C287-4385-B1FB-A1C18456AA6AQ34173479-5014E347-F12E-4F01-BAEE-352323ED9042Q34464783-1A933036-E2DB-42C5-B175-AD2C1D6ACD04Q34646376-C170CCF1-F944-4B48-A020-4AC21D37C57EQ34706019-7870964A-84D1-423C-B816-37365AF1CF1AQ34735167-F6472128-32A2-45BF-A5BE-2EC9A056411EQ35219157-6FEC5403-A201-4CBC-8A5A-8BB428FEAF40Q35238263-5307088E-980B-48B1-AAEB-978BA92D2119Q35794363-83EBB967-F950-49E4-A9C0-58494A905C6BQ36061177-ED03F9CF-40C1-46EE-827B-797B0AC8EB8CQ36251444-75E15FFA-4842-4A88-B3A1-B7A8958BBE93Q36311616-AB438F5A-D5BD-4F9C-AF8E-91F7D4A68B01Q36361597-0FB8AC64-DE9E-4816-BF3A-D82D2C3F1D27Q36369621-A19C35DF-8DAB-41D2-93A2-701DDB5FFBD1Q36424029-B8B43F5D-C3A2-4203-9390-81CA4ABBC684Q36609893-527C9883-C916-4544-A294-51E782E1D464Q37101469-E59A8D9C-A8C4-4EDA-B0F0-FBD2F0AC788CQ37131339-3EC42667-C64F-43B4-8CB6-967AE9A77265Q37328394-CEE2C334-C91D-4B30-9C6E-3ACD28E2F114Q37388751-C9C043BC-8A1F-40ED-9040-C054C9806627Q37746023-7AC1CB8F-AF9E-4BF8-A579-A27DBA22BB5CQ37764168-1D87BABE-FC3D-4C7F-90B2-C8ADF61EE2C2Q39491094-020966F3-03A1-48E6-8564-8C9B14D0DE39Q42493937-EF5E4351-ACAE-4DC1-B3B9-02637689EA3EQ46201393-B9FCDDB6-6546-4475-BDA4-44FC29F47CA1Q50352878-EDD8D643-30C5-49D3-969C-D60ACFF6C19CQ57640127-9D62F82E-5673-4032-B5A6-806E2C88F011Q58423595-EAA98EED-8819-4D7F-8EC0-24E70CC69BDC
P2860
KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
KIT is highly expressed in ade ...... ated with a favorable outcome.
@en
KIT is highly expressed in ade ...... ated with a favorable outcome.
@nl
type
label
KIT is highly expressed in ade ...... ated with a favorable outcome.
@en
KIT is highly expressed in ade ...... ated with a favorable outcome.
@nl
prefLabel
KIT is highly expressed in ade ...... ated with a favorable outcome.
@en
KIT is highly expressed in ade ...... ated with a favorable outcome.
@nl
P2093
P2860
P50
P1433
P1476
KIT is highly expressed in ade ...... ated with a favorable outcome.
@en
P2093
Abir Al Ghuzlan
Alain Fourquet
Brigitte Sigal-Zafrani
Caroline Chnecker
Jerzy Klijanienko
Marick Laé
Paul Fréneaux
Rémy Salmon
Sandy Azoulay
Solange Merle
P2860
P2888
P304
P356
10.1038/MODPATHOL.3800483
P577
2005-12-01T00:00:00Z
P5875
P6179
1019046111